3Lutterotti A,Martin R.Getting specific:monoclonal antibodies in multiple sclerosis[J].Lancet Neurol,2008,7(6):538-547.
4Stuve O,Bennett JL.Pharmacological properties,toxicology and scientific rationale for the use of natalizumab (Tysabri) in inflammatory diseases[J].CNS Drug Rev,2007,13(1):79-95.
5Polman CH,O'Connor PW,Havrdova E,et al.A randomized,placebo-controlled trial of natalizumab for relapsing multiple sclerosis[J].N Engl J Med,2006,354(9):965-967.
6Calabresi PA,Giovannoni G,Confavreux C,et al.The incidence and significance of anti-natalizumab antibodies:results from AFFIRM and SENTINEL[J].Neurology,2007,69(14):1386-1387.
7Rudick RA,Stuart WH,Calabresi PA,et al.Natalizumab plus interferon beta-1a for relapsing multiple sclerosis[J].N Engl J Med,2006,354(9):911-923.
8Balcer LJ,Galetta SL,Calabresi PA,et al.Natalizumab reduces visual loss in patients with relapsing multiple sclerosis[J].Neurology,2007,68(16):1299-1304.
9Oturai AB,Koch-Henriksen N,Petersen T,et al.Efficacy of natalizumab in multiple sclerosis patients with high disease activity:a Danish nationwide study[J].Eur J Neurol,2009,16(3):420-423.
10Yousry TA,Major EO,Ryschkewitsch C,et al.Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy[J].N Engl J Med,2006,354(9):924-933.
